We were excited to learn that our partners at Sage therapeutics have published trials of a formulation of the neurosteroid allopregnanolone for postpartum depression treatment. Another neuroactive steroid completed Phase 2 trials for Major Depressive Disorder and was recently designated FDA Breakthrough Status. This work seems to validate the studies we and others have done over the years characterizing the biology of neurosteroids, which act potently at GABAA receptors to potentiate inhibition. Current work in our lab seeks to clarify receptor classes at which neurosteroids act at therapeutic concentrations.
